Skip to main content
. 2024 Feb 12;15:1280. doi: 10.1038/s41467-024-45520-8

Fig. 7. miR-28-5p targets Rap1b to stimulate the expression of inflammatory cytokines via NF-κB.

Fig. 7

a The potential targets of miR-28-5p were predicted by integrating the results of two databases (TargetScan and miRDB). b BMDMs were treated with miR-28-5p for 24 h, the putative targets were analyzed by western blot. c The predicted binding motif between miR-28-5p and RAP1B. The wild-type or a mutated binding site between miR-28-5p and Rap1b was cloned into pmirGlo vector. BMDMs were co-transfected with either miR-NC control or miR-28-5p mimics for 24 h, the luciferase activity was then measured (n = 4 independent experiments per group, miR-NC mimic versus miR-28-5p mimic, for control, P = 0.99, for Rap1b WT, P = 0.0020, for Rap1b MUT, P = 0.98). d BMDMs were treated with miR-28-5p mimics or miR-28 inhibitor for 24 h, proteins that affecting NF-κB signaling were analyzed by western blot. e BMDMs were treated with miR-28-5p mimics or miR-28 inhibitor for 24 h, cellular distribution of p65 were analyzed by immunofluorescence staining. f The signaling pathway through which miR-28-5p target Rap1b to stimulate the expression of inflammatory cytokines via NF-κB. Data are presented as mean ± SEM. n = 6 mice per group. *P < 0.05, **P < 0.01, ***P < 0.001, NS no significant difference, one-way ANOVA. Source data are provided in the Source Data file.